WuXi PharmaTech (Cayman), Inc. (ADR) (NYSE:WX)
China-based pharmaceutical and biotechnology R&D outsourcing company which provides a integrated portfolio of laboratory and manufacturing services in the drug discovery and development process to pharmaceutical and biotechnology companies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Stock could be a buyout candidate. Company has been growing steady since its IPO and still hasn't surpassed the IPO price of $14 as of Feb 10. Stock should be in at least in the low $20 range
Recs
It has a strong balance sheet and has the growing Chinese market. Plus, the population is aging in the developed world...this could be a huge one.
Recs
Intrinsic:10.46
Recs
high quality, inexpensive pharmaceutical R&D.
Recs
Chinese BioTech & Pharma Outsourcing company.
Recs
China pharm is in the rising
Recs
Outsourcing is and will continue to be a hot ticket item. Outsourcing pharma R&D is an interesting concept.
Recs
Recs
I like the CRO business (contract research...not drug development, as some seem to think) as a secular trend, and WuXi is the lower-cost Chinese solution. Perhaps not the greatest business moat, but at this price, I'll take the risk.
Recs
Chinese medical services
Recs
Pharmaceutical R&D is a very expensive part of the pharmaceutical market. I feel their will be a paradigm shift on how global pharmaceutical companies approach research, one of the results will be more outsourcing and collaborations.. WuXi is positioned well to take advantage of this shift.
Recs
8x trailing EBITDA. 75% earnings growth. Market leader in China. Outsourcing is a natural in down markets. The pharma customer base is steady in a down market. Good risk-reward.
Recs
excellent company, great growth....PE 6.21 get some balls and buy !
Recs
Still a way to go...down. Not a buy...yet.
Recs
Recs
No-brainer.
Booming industry in booming country at a great price!
Recs
For some reason I foresee this first quarter doubled profit company performing well in the future.
Recs
The looming recession that bernanke and the whole federal reserve gang have set this country towards will send alot of investors into the pharmaceutical's sector--being the traditional recessionary savior to say the least. Plus, most pharmaceutical stocks have been beaten down this past winter, and I see a reversal across the entire sector. Also, those companies already on a run will continue due to the upward momentum this summer from key reversals and upgrades throughout the sector.
Recs
While the Chinese market is open, someone has to be the top dog in the Chinese pharma market and my bet is on these guys. Well run, low costs in a usually high cost sector, huge and growing market.
Recs
FDA gave some good coments with this one, fast short run for a blast cash grab.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 38 : 1 2 Next »